loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in MoonLake Immunotherapeutics submits sonelokimab BLA Sep 30, 2026, 5:48 PM ETMoonLake Immunotherapeutics (MLTX) StockUCBJFBy : Jonathan Block, SA News Editor MoonLake Immunotherapeutics (MLTX) submitted a BLA to the US FDA seeking approval of sonelokimab for hidradenitis suppurativa. The company has completed two phase 3 studies, VELA-1 and VELA-2, of the tri-specific nanobody in adults. It also has the phase 3 VELA-TEEN To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Recommended For You
document fetched 2026-10-01 03:03 · canonical https://seekingalpha.com/news/4648802-moonlake-immunotherapeutics-submits-sonelokimab-bla?feed_item_type=news